Background. Heart failure (HF) is highly prevalent and associated with high mortality in chronic kidney disease (CKD). However, the pathophysiology of cardiac dysfunction in CKD, especially in the early asymptomatic stage, is not well understood. We studied subclinical cardiac dysfunction in asymptomatic CKD patients without comorbid cardiac disease or diabetes mellitus by evaluating peak cardiac performance. Methods. In a cross-sectional study (n ¼ 130) we investigated 70 male non-diabetic CKD patients (21 CKD stage 2-3a, 27 CKD stage 3b-4 and 22 CKD stage 5) employing specialized cardiopulmonary exercise testing to measure peak cardiac output and cardiac power output non-invasively. Data from 35 age-matched healthy male volunteers were obtained for comparison. In addition, as a positive control, data from 25 agematched male HF patients in New York Heart Association class II and III were also obtained. Results. The study subjects showed a graded reduction in peak cardiac power, with 6.13 6 1.11 W in controls, 5.02 6 0.78 W in CKD 2-3a, 4.59 6 0.53 W in CKD 3b-4 and 4.02 6 0.73 W in CKD 5, although not as impaired as in HF, with 2.34 6 0.63 W (all P < 0.005 versus control). The central haemodynamic characteristics of the cardiac impairment in CKD mirrored that of HF, with reduced flow and pressure-generating capacities, reduced chronotropic reserve and impaired contractility. Conclusions. The study demonstrates for the first time impaired peak cardiac performance and cardiac functional reserve in asymptomatic CKD patients. The evidence of myocardial dysfunction in the absence of comorbid cardiac disease and diabetes warrants further evaluation of current pathophysiological concepts of cardiovascular disease in CKD.
we measured peak cardiac power output, non-invasively, during a cardiopulmonary exercise test (CPX) [9, 10] .
In the present study, we tested the hypothesis that asymptomatic CKD patients have impaired peak cardiac power output and hence reduced cardiac functional reserve compared with healthy subjects. Moreover, we tested CKD patients without primary cardiac disease or DM to study the effect of CKD-specific factors in isolation.
M A T E R I A L S A N D M E T H O D S

Study subjects
Asymptomatic male CKD patients (n ¼ 70) were recruited from the renal outpatient clinic of a tertiary UK referral centre for CPX. The inclusion and exclusion criteria are listed in Table 1 . The present study is limited to male gender alone to minimize confounders that arise due to the effect of gender and body composition on central haemodynamics [11] [12] [13] . Venous blood samples were taken at the time of recruitment to assay serum creatinine, urea, haemoglobin (Hb), serum calcium, inorganic phosphate and parathyroid hormone (PTH). Urine samples were assayed for urine protein:creatinine ratio. Estimated glomerular filtration rate (eGFR) was calculated using the fourvariable Modification of Diet in Renal Disease (MDRD) formula [14] . CPX data from contemporaneous healthy male volunteers (n ¼ 35) who participated in a previous study in the unit were obtained for comparison. For positive controls, the CPX data from age-matched male HF patients in New York Heart Association (NYHA) class II and III (n ¼ 25) who underwent CPX testing on clinical grounds were used for comparison. The control subjects and the HF patients were drawn from the same population as the CKD patients and all study participants underwent CPX tests using the same protocols and procedures. The study was approved by the Research Ethics Committee [Ref : 11/ H1310/8 and 05/Q1205/151 (control)]. All subjects provided informed written consent before participation. These clinical investigations conformed with the Declaration of Helsinki.
Sample size
Based on the results of the pilot study [9] , to demonstrate a 10% difference in peak cardiac power output (CPO max ) between study groups and healthy controls (with 90% power), a minimum of 11 patients per group was required.
Cardiopulmonary exercise tests
CPO max was determined non-invasively during maximal CPX. Full methodological details have been described in previous reports [15, 16] . The validity and reliability of the methods have been extensively studied in the past [17] [18] [19] [20] [21] . Furthermore, over the past 20 years several studies have been published using the same techniques [11, 15, 16, 22, 23] . A summary of the methodology is presented here.
Resting measures. The subjects had resting measurements for O 2 consumption and CO 2 production, respiratory rate and cardiac output (CO) using a Medgraphics CardiO 2 Analytic System (Medgraphics, St. Paul, MN, USA). Resting CO was calculated using the Collier CO 2 rebreathing method [17, 24] . The Collier's equilibration method has been shown to have good correlation with thermodilution techniques at rest [18] and is easy to use and therefore it was utilized for resting measurements.
Determination of aerobic capacity (VO 2max ). Subjects then underwent an incremental exercise test on a treadmill according to a standard Bruce protocol and every 3 min the speed and incline of the treadmill were increased according to the protocol until the subjects reached volitional exhaustion. Throughout the treadmill test, O 2 consumption, CO 2 production, end-tidal partial pressure of CO 2 , tidal ventilation and respiratory rate were measured using breath-to-breath analysis. Ventilatory ('anaerobic') threshold was measured by the Vslope method [25] . A 12-lead electrocardiogram was monitored throughout, and the subject's heart rate (HR) was obtained from this. Blood pressure (BP) was measured by auscultation and sphygmomanometry at rest and at 3-min intervals up to and including maximal exercise.
Determination of CO. After resting at least 40 min, a second treadmill test was performed. The speed and incline of the treadmill were adjusted manually. The subjects exercised on the treadmill to 95% of their VO 2max as established in the incremental exercise test. Two or three CO measurements were made using the Defare's CO 2 rebreathing method [26] . The Defare's method was chosen because this method has been shown to correlate well with CO obtained with thermodilution techniques during exercise [19] . Blood pressure was measured using a sphygmomanometer after each determination of CO. The formulae used to calculate haemodynamic variables are listed in Table 2 .
Statistical analysis
CPO max was the primary outcome measure. Comparison of CPO max among the study groups, controlling for age, was performed using analysis of covariance (ANCOVA). Differences between any two groups were tested using Bonferroni post hoc test. Similar analyses were performed for peak CO, peak mean blood pressure, HR reserve and cardiac reserve. Normality of data was verified using normal Q-Q plots and numerical methods (Shapiro-Wilk test). All data were normally distributed except for serum PTH. The association between CPO max and biochemical parameters was tested using Pearson's correlation. 
In order to determine the independent predictors of cardiac reserve in CKD, a stepwise multiple regression analysis was used incorporating the haemodynamic, demographic and biochemical variables with significant correlation (P < 0.05) with cardiac reserve on a univariate analysis.
To evaluate the effect of beta blockers on the haemodynamic parameters, the CKD subjects were divided into two groups based on whether or not they were on beta blockers. A linear regression, controlling for eGFR, was employed to test the difference between the groups.
Results are presented as mean 6 SD. For Bonferroni post hoc test, since there were five groups and 10 pairwise comparisons, a strict criterion for statistical significance, P < 0.005, was employed. For all other analyes, P < 0.05 was considered statistically significant. SPSS 17.0 (IBM, Armonk, NY, USA) statistics software was used in the analysis.
R E S U L T S
Subject characteristics
Anthropometric and biochemical characteristics of the study subjects are listed in Table 3 and the aetiologies of CKD are listed in Table 4 . There were 70 male CKD patients with a mean age of 48.4 6 12.6 years covering the spectrum of CKD from Stages 2 to 5 (CKD 2-5, pre-dialysis). None of the patients had a history of primary cardiac disease (ischaemic, arrhythmic or valvular) or DM. Patients had no cardiac symptoms and thus all were in NYHA class I. No patient had electrocardiographic evidence or symptoms of angina pectoris, myocardial ischaemia or arrhythmia during exercise testing. None had uncontrolled hypertension (mean resting systolic blood pressure was 113.9 6 12.5 mmHg and diastolic blood pressure was 72.3 6 8.1 mmHg). Of the 70 patients, 61.4% were receiving angiotensin-converting enzyme inhibitors (ACE-Is), 34.8% angiotensin receptor antagonists and 20.0% b-adrenoceptor antagonists. The average number of antihypertensive agents taken per patient in CKD 2-3a, CKD 3b-4 and CKD 5 was 1.2, 1.6 and 1.7, respectively. For comparison, Table 3 shows data from contemporaneous healthy male volunteers (n ¼ 35) and male patients with confirmed HF (n ¼ 25) in functional NYHA classes II and III.
CPX parameters
All CKD patients successfully performed 'high-intensity' CPX to volitional exhaustion with a mean duration of 10.5 6 2.9 min (Bruce protocol equivalent, P ¼ NS versus controls), a mean peak respiratory exchange ratio (RER) of 1.16 6 0.09, a peak end tidal pCO 2 (ETpCO 2 ) of 37.2 6 5.9 mmHg and a maximal aerobic capacity (VO 2max ) of 2.51 6 0.53L/min. The healthy volunteers exercised for 11.5 6 3.7 min (Bruce protocol) with a mean peak RER of 1.21 6 0.13, ETpCO 2 of 38.2 6 4.9 mmHg and VO 2max of 3.10 6 0.62 L/min. The HF patients exercised for 5.5 6 2.8 min (Bruce protocol equivalent, P < 10 À6 versus controls) with a mean RER of 1.1 6 0.2, ETpCO 2 of 29.9 6 8.7 mmHg and VO 2max of 1.54 6 0.38 L/min.
Resting haemodynamics
The resting haemodynamic parameters of the study groups, including HR, mean blood pressure, CO, systemic vascular resistance (SVR) and cardiac power output, are presented in Table 5 . The resting haemodynamic parameters were not significantly different between the study groups except for mean blood pressure between the control and HF (P < 0.005) and cardiac power output between the control and HF groups (P < 0.005). Significant differences were also demonstrated for cardiac power output between the CKD 2-3a and HF groups and for CO between the CKD 2-3a and HF groups (P < 0.005).
Peak haemodynamics
Impaired peak cardiac power output (CPO max ) and cardiac reserve in CKD. CPO max showed a graded decline across the study groups (Table 6 and Figure 1 ). Compared with healthy Table 2 . List of formulae used in the study
DBP, diastolic blood pressure; SBP, systolic blood pressure; CPO, cardiac power output; VDC, vasodilatory capacity.
) is the conversion factor to convert CPO into the SI unit of power, Watts. Table 3 . Body composition and biochemical characteristics of study subjects BMI, body mass index; BSA, body surface area; PCR, protein:creatinine ratio. P-value is for analysis of variance across the study groups.
controls, all CKD groups and the HF group demonstrated a statistically significant (P < 0.005) difference in CPO max and in cardiac reserve (Figures 1 and 2) . Furthermore, compared with CKD 2-3a, the CPO max and cardiac reserve were significantly impaired in CKD 5 and HF (P < 0.005). The difference between CKD 2-3a and CKD 3b-4 did not reach statistical significance.
Impaired peak CO and peak mean arterial pressure in CKD. Figure 3 shows the differences in peak CO and peak mean arterial pressure (MAP), the flow and pressure-generating capacities of the heart, respectively, across the study groups. Peak CO was significantly lower in all study groups compared with controls (P < 0.005) and peak MAP was significantly lower in the CKD 5 and HF groups compared with controls (P < 0.005).
Impaired peak HR and HR reserve in CKD. The peak HR of the study groups is presented in Table 6 . The HR reserve, measured as the difference between peak and resting HR and adjusted for age (AHRR) [27] , was significantly lower in all study groups compared with controls (P < 0.005) ( Figure 4 ).
Peak SVR across CKD groups. The peak SVR of the study groups is shown in Table 6 .
Association between CPO max and CKD-related biochemical parameters CPO max had a significant positive correlation with eGFR, Hb and serum bicarbonate and a significant negative correlation with urea, PTH and inorganic phosphate. No correlation existed with serum calcium and urine protein:creatinine ratio ( Figure 5 ). Independent associations of individual biochemical variables with CPO max could not be assessed because of strong collinearity among the biochemical parameters.
Effect of beta blockers on central haemodynamics in CKD patients
Linear regression was performed, controlling for eGFR, to compare haemodynamic parameters between CKD patients who were on beta blockers and those who were not. Results showed that there were no significant differences in peak CPO (D ¼0.03W, P ¼ 0.96), peak CO (D¼ 0.13 L/min, P ¼ 0.54) and peak MBP (D ¼ 3.72 mmHg, P ¼ 0.23) between the two groups. However, significant differences were present between the mean peak HR and mean peak SV between the groups. The mean peak HR was lower in the beta blocker group by 26.85 / min (P < 10 À3 ), whereas the mean peak SV was greater in the beta blocker group by 26.63 mL (P < 10
À3
), offsetting the reduction in peak HR.
Comparison between cardiac functional reserve measured by CPO max and VO 2max in CKD patients
Simultaneous measurements of CPO max and peak O 2 consumption (VO 2max ) in CKD allowed evaluation of the determinants of these parameters in CKD. Furthermore, simultaneous measurements of VO 2 and CO at rest and peak exercise enabled measurement of arteriovenous differences in O 2 concentration [C av O 2 ] at rest and peak exercise for the first time in CKD patients using Fick's equation VO 2 ¼ CO Â C av O 2 (Tables 5 and 6 ).
Univariate and multivariate analyses. Tables 7 and 8 show the haemodynamic, biochemical and demographic parameters that are significantly associated with cardiac reserve determined by measuring CPO at rest and peak exercise (DCPO) and cardiac reserve determined by measuring VO 2 at rest and peak exercise (DVO 2 ) on univariate analyses. Table 9 shows the independent predictors identified on a stepwise multiple regression analysis. For CPO reserve , the increment in the pressure-generating capacity of the heart (DMAP) was the strongest independent predictor. No independent association was demonstrated with Hb, systemic vasodilatory capacity (DSVR) or increment in peripheral O 2 extraction No independent association was demonstrated with DMAP or eGFR.
D I S C U S S I O N
The present study significantly advances our knowledge of the impact of CKD on cardiac pump function. The results of the study support the hypothesis that cardiac performance, as represented by CPO max and cardiac reserve, is significantly impaired in CKD compared with healthy controls. Moreover, the impairment was proportional to the severity of CKD. The cardiac performance of CKD patients was shown to lie between that of healthy controls and patients with symptomatic HF. Since we studied asymptomatic, non-diabetic CKD patients with no overt cardiac disease and with controlled blood pressure, our results show that CKD per se is associated with cardiac dysfunction even in early CKD and when asymptomatic. This dysfunction is only revealed under conditions of peak exercise, suggesting that in CKD patients, like conventional cardiac failure, compensatory mechanisms maintain resting cardiac performance within normal limits. Although cardiac 'structural' changes have been studied in the past in asymptomatic CKD patients, the present study has demonstrated 'functional' impairment for the first time in such FIGURE 1: CPO max showing graded decline across the study groups. *P < 0.005 versus controls, # P < 0.005 versus CKD 2-3a on Bonferroni post hoc test.
FIGURE 2: Cardiac reserve (DCPO) showing graded decline across the study groups. The peak performance (CPO max ) of the heart is more discriminatory among different groups than the resting measure (CPO rest ). *P < 0.005 versus controls, # P < 0.005 versus CKD 2-3a on Bonferroni post hoc test. The central haemodynamic alterations underlying the impaired peak cardiac performance in CKD mirror the changes in symptomatic HF patients, albeit of lesser magnitude. The study shows cardiac power, an index of 'myocardial contractility', is impaired in CKD. The study also shows impairment in cardiac power results from impairment in both flow and pressure-generating capacities of the heart akin to HF. Furthermore, the study also revealed impaired 'chronotropic reserve' in CKD not unlike HF. In summary, the central haemodynamic changes seen in symptomatic HF appear to be evolving in asymptomatic CKD patients even in the absence of any primary cardiac disease.
HF and CKD share several common pathophysiological mediators with the potential to cause progressive myocardial dysfunction. These include renin-angiotensin-aldosterone system (RAAS) activation, sympathetic activation, pro-inflammatory cytokines and myocardial wall stress [28] [29] [30] [31] [32] [33] . In HF, these mediators were shown to cause direct cardiomyocyte toxicity by inducing apoptosis and necrosis, and pathological hypertrophy resulting in progressive myocardial dysfunction [34] [35] [36] [37] [38] [39] . The existence of the above mediators in the uremic milieu raises the possibility of similar pathogenesis of myocardial dysfunction in CKD.
The above similarities between CKD and HF in the biomechanics of myocardial dysfunction and the mediators of such dysfunction draw our attention to potential therapies to attenuate or reverse the process. Whereas in HF, the benefits of RAAS blockade and beta blockade in preventing the progression of myocardial dysfunction have been shown consistently [40] [41] [42] , the evidence for such treatments in uraemic cardiomyopathy is still lacking.
A standard CPX is normally employed to measure exercise capacity, VO 2max . We used physical exercise as a physiological, non-invasive stimulus to drive the heart to its peak performance to measure CO and CPO max . Since CPX is the study tool, it is natural to draw a comparison between CPO max and VO 2max . Indeed, VO 2max has recently been proposed as a measure of 'functional cardiac reserve' in CKD [43] . However, evidence from HF research demonstrates that VO 2max can be influenced by non-cardiac factors such as muscle deconditioning, age, gender, anaemia and motivation [44] . Instead, it has been shown that a more direct assessment of cardiac performance can be achieved by measuring CPX-derived haemodynamic variables rather than just VO 2max [44, 45] . Indeed, in head-to-head comparisons, CPO max has repeatedly been shown to be the best predictor of prognosis in HF compared with VO 2max [16, 46] . In the present study, the simultaneous measurement of CO and VO 2max enabled us to compare the determinants of cardiac reserve in CKD as measured by CPO max or VO 2max . Our detailed analysis undermines the assumption that VO 2max serves as a convenient measure of 'functional cardiac reserve'. Our data show that the increment in arteriovenous O 2 difference was the strongest predictor of VO 2 reserve. This limitation in increasing peripheral O 2 extraction is likely to be related to anaemia, plus possible uremic skeletal myopathy, although further studies will be required to fully elucidate the role of central, peripheral and biochemical determinants of VO 2max in CKD.
Our analysis demonstrated that Hb is an independent predictor of VO 2max but not of CPO max . Studies that simultaneously measured peak CO and VO 2max before and after erythropoietin therapy/haemodilution have also shown that altered Hb affects VO 2max measures but not peak CO [47] . It must be acknowledged that our evaluation is limited to statistical analysis of a cross-sectional study. Further longitudinal studies in CKD may be worthwhile in the future to evaluate the effect of anaemia correction on central haemodynamics.
A criticism of employing CPX in the evaluation of cardiac performance is that inadequate patient effort could be a confounder. In our study, all CKD patients exercised above the anaerobic threshold with a mean RER >1.1 in all three CKD groups. All patients were encouraged to exercise until volitional FIGURE 3: Peak cardiac output (Pk CO) and peak mean arterial pressure (Pk MAP) across the study groups showing graded decline in flow and pressure-generating capacities of the heart, respectively. *P < 0.005 for Pk CO and # P < 0.005 for Pk MAP versus controls on Bonferroni post hoc test. Cardiac power output and cardiac reserve were not shown to be influenced by beta blockade therapy in the present study. The reduction in peak HR associated with beta blockade was shown to be offset by the increase in SV and hence there was no were treated with RAAS blockade, but if this has affected the results, the effect was uniform. Furthermore, as CO and afterload have a linear inverse relationship [48] , and CPO max is an index that incorporates measures of both volume and pressure, the changes in arterial pressure are offset by changes in the volume generated. Hence, CPO max remains afterload independent, akin to other pressure-volume indices such as stroke work, stroke work index, etc. [48] .
As the first-ever study exploring the impact of CKD directly on peak cardiac power, we utilized a cross-sectional study design. A longitudinal study design in the same patients as the disease progresses would be better suited to demonstrate a causal relationship between uraemia and cardiac dysfunction. However, most aetiologies of CKD (especially in the absence of comorbid cardiovascular disease or DM) run an indolent course progressing over many years making such a study challenging to undertake. Alternatively, a longitudinal study design testing interventions such as kidney transplantation or novel dialysis strategies would be highly pertinent in the future.
In conclusion, the study has demonstrated that cardiac functional reserve is impaired in asymptomatic CKD patients and the dysfunction appears to be associated with CKD alone in the absence of cardiovascular comorbidities. The haemodynamic characteristics of such impairment demonstrate a failing myocardium in CKD, thus highlighting the existence of a cardiomyopathic component in the pathophysiology of cardiovascular disease in CKD. As the current concepts of the pathogenesis of cardiovascular disease in CKD do not adequately explain this phenomenon, further investigation into the aetiology and its management is paramount.
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